This core's mission is to facilitate translational and laboratory-based research performed by all program investigators. The core supports 4 functions: 1) processing and cryopreservation of primary AML and MDS samples; 2) annotation of primary samples with pathologic, cytogenetic and flow cytometry data; 3) annotation of primary AML samples with genomic and functional data; and 4) maintain a bank of AML cell lines, primagrafts and in vitro models suitable for functional assays. As of November 2018, 12,790 bone marrow samples have been banked from 3,590 unique patients with hematologic malignancies. All of these samples were obtained from patients enrolled on IRB-approved sample collection protocol DF/HCC 01-206: Blood and Bone Marrow Sample Collection for Research Studies in Patients with Hematologic Malignancies, Bone Marrow Disorders, and Normal Donors. The bank includes samples from 1473 patients with AML and 634 patients with MDS. The samples have been extensively used to support clinical and laboratory research over the last five years in support of drug development, analysis of oncogene function and prognosis, development of BH3 profiling, creation of a large bank of genomically defined PDX models of AML, and other laboratory studies.
This Shared Resource Core will collect blood and/or marrow samples from patients with AML or MDS and preserve viable cells, RNA, and DNA from adult patients receiving treatment at DFCI or BWH, along with annotated clinical and genomic data from these patients. The Core makes these samples available for clinical or research studies carried out in each of the projects in this grant.
Showing the most recent 10 out of 376 publications
